Back to Search
Start Over
GH Dose Reduction Maintains Normal Prepubertal Height Velocity After Initial Catch-Up Growth in Short Children
- Source :
- The Journal of clinical endocrinology and metabolism. 104(3)
- Publication Year :
- 2018
-
Abstract
- Context GH responsiveness guides GH dosing during the catch-up growth (CUG) period; however, little is known regarding GH dosing during the prepubertal maintenance treatment period. Objective To evaluate whether SD score (SDS) channel parallel growth with normal height velocity can be maintained after CUG by reducing the GH dose by 50% in children receiving doses individualized according to estimated GH responsiveness during the catch-up period. Design and Settings Prepubertal children (n = 98; 72 boys) receiving GH during CUG (GH deficient, n = 33; non-GH deficient, n = 65), were randomized after 2 to 3 years to either a 50% reduced individualized dose (GHRID; n = 27; 20 boys) or unchanged individualized dose (GHUID; n = 38; 27 boys). Another 33 children (25 boys) continued a standard weight-based dose [43 µg/kg/d (GHFIX)]. Main Outcome Measures The primary endpoint was the proportion of children with ΔheightSDS within ±0.3 at 1 year after GH dose reduction compared with two control groups: GHUID and GHFIX. The hypothesis was that heightSDS could be maintained within ±0.3 with a reduced individualized GH dose. Results For the intention-to-treat population at 1 year, 85% of the GHRIDgroup maintained ΔheightSDS within ±0.3 vs 41% in the GHUIDgroup (P = 0.0055) and 48% in the GHFIXgroup (P = 0.0047). The ΔIGF-ISDS in the GHRID group was -0.75 ± 1.0 at 3 months (P = 0.003) and -0.72 ± 1.2 at 1 year compared with the GHUID group (0.15 ± 1.2; P = 0.005) and GHFIX group (0.05 ± 1.0; P = 0.02). Conclusions Channel parallel growth (i.e., normal height velocity) and IGF-ISDS levels within ±2 were maintained after completed CUG using a 50% lower individualized dose than that used during the CUG period.
- Subjects :
- Male
medicine.medical_specialty
Adolescent
Endocrinology, Diabetes and Metabolism
Clinical Biochemistry
Population
030209 endocrinology & metabolism
Context (language use)
Biochemistry
03 medical and health sciences
0302 clinical medicine
Endocrinology
Internal medicine
Clinical endpoint
Medicine
Humans
Drug Dosage Calculations
Dosing
Prospective Studies
education
Child
Growth Disorders
education.field_of_study
030219 obstetrics & reproductive medicine
Dose-Response Relationship, Drug
business.industry
Human Growth Hormone
Biochemistry (medical)
Body Weight
Outcome measures
Treatment period
Body Height
Recombinant Proteins
Intention to Treat Analysis
Treatment Outcome
Child, Preschool
Dose reduction
Female
business
Follow-Up Studies
Subjects
Details
- ISSN :
- 19457197
- Volume :
- 104
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- The Journal of clinical endocrinology and metabolism
- Accession number :
- edsair.doi.dedup.....fb1109a736d410eebcc26390ac8947db